FAPI-PET predicts treatment response in patients with rheumatoid arthritis

In this study, they further analyzed data from 19 patients to determine whether FAPI-PET could help predict treatment responses. All of the patients had high or moderate disease activity and underwent PET/CT exams at baseline, as well as standard F-18 FDG PET/CT scans for comparison. Subsequent treatments included conventional DMARDs (including methotrexate, leflunomide, cyclophosphamide, and tripterygium wilfordii), and synthetic DMARDs (including etanercept, adalimumab, and Janus Kinase inhibitors). Six patients received additional prednisone, and six patients had nonsteroidal anti-inflammatory drugs.Representative Ga-68 FAPI-04 and F-18 FDG-PET/CT images of responders at three month follow-up. Patient #11 was a 50-year-old man with 28 affected joints detected in PET/CT. Joint activity decreased after treatment with Tripterygium wilfordii, methotrexate, adalimumab, and prednisone. In patient #8 (a 65-year-old woman), Ga-68 FAPI-04 PET/CT showed 12 affected joints. Joint activity decreased from baseline after three months of treatment with Tripterygium wilfordii and methotrexate.Image courtesy of EJNMMI Research According to the data, 11 patients were responders (major response in two patients, moderate response in four patients, and minor response in five patients), and eight patients were non-responders. Both baseline Ga-68 FAPI-04 and FDG F-18 FDG radiotracer were higher on PET/CT in responders versus nonresponders, with Ga-68 FAPI-04 showing higher uptake than F-18 FDG...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Subspecialties Nuclear Radiology Source Type: news